1. Jones P, Wilcoxen K, Rowley M, et al. Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination. J Med Chem. 2015;58(8):3302–14.
2. O’Sullivan Coyne G, Chen AP, Meehan R, et al. PARP inhibitors in reproductive system cancers: current use and developments. Drugs. 2017;77(2):113–30.
3. Tesaro. Tesaro announces expanded development program for niraparib focused on the treatment of front-line metastatic ovarian and lung cancer and metastatic breast cancer. 2017. http://www.tesarobio.com . Accessed 3 Apr 2017.
4. Tesaro. ZEJULA™ (Niraparib): US prescribing information. 2017. https://www.accessdata.fda.gov/ . Accessed 29 Mar 2017.
5. European Medicines Agency. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use. 2016. http://www.ema.europa.eu . Accessed 3 Apr 2017.